INTRODUCTION
Immunotherapy with gene-modified T cells expressing a tumorreactive chimeric antigen receptor (CAR) is a rapidly evolving research field.
1,2 Impressive responses have been achieved in some patients with refractory acute lymphoblastic leukemia, chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma after infusing autologous T cells expressing a CAR specific for the B-lineage molecule CD19. [3] [4] [5] [6] [7] [8] Tumor regression appears to correlate with the level and duration of CAR-T-cell engraftment, and the subset of patients in whom CD19 CAR-T cells proliferate and persist in the blood have continuous on-target depletion of normal CD19 + B cells and are more likely to remain in remission. [3] [4] [5] [6] [7] [8] [9] [10] Designing optimized CARs with enhanced signaling to sustain T-cell proliferation and survival may improve the efficacy of CAR-T cells. [11] [12] [13] [14] [15] [16] Generating cell products derived from subsets of CD8 + and CD4 + T cells with superior intrinsic abilities for proliferation and survival after transfer may also enhance efficacy. CD8 + and CD4 + T cells exist as naive (T N ), effector (T E ) and memory (T M ) sub-populations delineated by changes in surface phenotype after antigen exposure. T M are further divisible into central (T CM ) and effector memory (T EM ) subsets that differ in phenotype, transcriptional profile and self-renewal capacity. [17] [18] [19] Mouse models have defined lineage relationships of these CD8 + T-cell subsets. Fate mapping of the differentiation of T N in response to antigen supports a model in which T N differentiate in a linear manner to long-lived T CM that serve as stem cells for antigen-specific immune responses, and to shorter-lived T EM and T E cells. 18, [20] [21] [22] CD4 + T cells also express T N , T CM and T EM surface markers and provide help for cytolytic T cells and antibodyproducing B cells. 23 Clinical trials in cancer have not considered the derivation of CAR-T cells from defined subsets despite evidence for synergy between CD8 and CD4 cells in an HIV CAR trial that may be further enhanced by subset selection; 24, 25 rather CD3 + T cells are selected and nonspecifically activated from peripheral blood mononuclear cells (PBMC) with anti-CD3 mAb before transduction and expansion. This strategy simplifies manufacturing of cell products but the frequency of CD8 + and CD4 + T-cell subsets in the blood can differ markedly in individuals because of age, pathogen exposure and the lymphocytotoxic effects of chemotherapy. 26, 27 As a consequence, CAR-T-cell products prepared from PBMC contain divergent proportions of CD8 + and CD4 + T-cell subsets, and this heterogeneity could contribute to the differences in efficacy and toxicity observed in clinical trials. 3, 5, 6, 10 Here, we purified individual CD8 + and CD4 + T-cell subsets from normal donors and patients with B-cell malignancies before their genetic modification with a lentiviral vector encoding a CAR, enabling analysis of the functional activity of subsets and subset combinations in vitro and in vivo. Our data show that the composition of CAR-T-cell products profoundly influences function and therapeutic efficacy, and reveals synergy between CD4 + and CD8 + CAR-T cells in mediating antitumor responses in vivo.
MATERIALS AND METHODS Cells
293 T cells (ATCC_CRL-11268) were cultured in Dulbecco's modified Eagle's medium/10% fetal calf serum and 100 U/ml penicillin/streptomycin and K562 (ATCC_CCL-243), K562/CD19, 28 K562/ROR1, 13 Raji (ATCC_CCL-86), Raji/ffluc 29 and JeKo-1 (ATCC_CRL-3006) in RPMI-1640/5% fetal calf serum and 100 U/ml penicillin/streptomycin. Cell lines were tested monthly for the absence of mycoplasma. T cells were cultured in RPMI-1640/10% human serum, 100 U/ml penicillin/streptomycin, 4 mM L-glutamine, 50 μM β-mercaptoethanol and 50 U/ml interleukin-2 (IL-2). PBMC were isolated over Ficoll-Hypaque (Sigma, St Louis, MO, USA), CD4 + or CD8 + T cells were isolated by negative magnetic selection (Miltenyi, Bergisch Gladbach, Germany) and then labeled for CD4/CD8/CD45RO/CD62L. T N (CD45RO − / CD62L + ), T CM (CD45RO + /CD62L + ) and T EM (CD45RO + /CD62L − ) were sorted to 499% purity on a FACSAriaII. PBMC from CLL patients were used as autologous CLL samples.
Vector construction, preparation of lentivirus, generation of CAR-T cells and in vitro functional assays The CD19 CAR included an scFv of the CD19-specific mAb FMC63 (ref. 30) with a 218 linker 31 between the VL and the VH domains, the hinge region of IgG4 with a serine to proline substitution at position 10, the CD28 transmembrane region, a 4-1BB costimulatory domain, and intracellular CD3ζ. The CD19 CAR gene was linked to a truncated epidermal growth factor receptor (EGFRt) by T2A and cloned into the lentiviral vector epHIV7. 32 The ROR1-specific CAR was described previously. 33 Lentivirus was generated by transient transfection of 293 T cells 34 using psPAX2 and pMD2G packaging plasmids. T cells were activated with anti-CD3/CD28-beads (Life Technologies, Carlsbad, CA, USA), and transduced 1 day after activation by centrifugation at 800 × g for 90 min at 32°C with lentiviral supernatant supplemented with 1 μg/ml polybrene (Millipore, Billerica, MA, USA). T cells were enriched for EGFRt + cells by fluorescence-activated cell sorting and expanded with an irradiated B-lymphoblastoid cell line. 28 Functional in vitro assays were performed as described; cytotoxicity was analyzed by standard chromium release assays, cytokine levels by enzymelinked immunosorbent assay or Luminex assays; and proliferation of CAR-T cells by carboxyfluorescein succinimidyl ester dilution assays. 13 Immunophenotyping T cells were stained with combinations of the following conjugated mAbs: CD4, CD8, CD27, CD28, CD45, CD45RA, CD45RO, CD62L and matched isotype controls (BD Biosciences, Franklin Lakes, NJ, USA). Transduced T cells were stained with biotin-conjugated anti-EGFR antibody (ImClone Systems Incorporated, Bridgewater, NJ, USA) and streptavidin-PE (BD Biosciences). Flow cytometry was performed on a FACSCantoII and data analyzed with FlowJo (Treestar, Ashland, OR, USA).
Transfer of T cells in NOD/SCID/γc
− / − (NSG) mice Six-to 8-week-old female NSG mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA) or bred in-house, engrafted via tail vein with 5 × 10 5 Raji/ffluc cells, and 1 week later, injected intravenously with CAR-or control T cells that had been expanded with lymphoblastoid cell line for 8 or 9 days. Bioluminescence imaging was performed as described. 13 Peripheral blood was obtained by retro-orbital bleeding and erythrocytes were removed using ammonium-chloride-potassium lysis buffer. At least five mice per experimental group were used for data analysis to provide 81% power to detect an effect size of Figure 1a ). There was also heterogeneity in the proportions of T N , T CM and T EM subsets in individual normal donors and patients, with patient samples containing a significantly higher mean frequency of T EM and lower mean frequency of T N cells in both CD4 + and CD8 + subsets than normal donors (Figure 1b ). These data are consistent with the large variation in the frequency of CD4 and CD8 T cells in CAR-T-cell products reported in studies in which unselected peripheral T cells were transduced to generate T cells for adoptive therapy. 10, 35 
CD4
+ and CD8 + CAR-T cells are transduced efficiently and differ in effector function Strategies for purifying T-cell subsets have been developed, making it possible to prepare products derived from defined populations. 36 To provide insight into how heterogeneity in T-cell composition may affect therapy, we evaluated functions of purified CD4 functions in vitro and antitumor efficacy in vivo. It is noteworthy that the peak frequency of CAR-T cells derived from all CD4 + T-cell subsets, including CD4 + T EM that was incapable of eradicating tumor in a majority of mice, exceeded that of a curative dose of CD8 + T CM -derived CAR-T cells, illustrating the greater potency of CD8 + CAR-T cells derived from this subset (Figures 3f and 4e ; and data not shown).
+ CAR-T cells exhibit synergistic antitumor activity with CD8 + CAR-T cells In addition to direct tumor recognition, the production of abundant IL-2 by CD4 + CAR-T cells may augment proliferation, survival and efficacy of CD8 + CAR-T cells. Synergistic activity of CD4 and CD8 CAR-T cells has been observed in murine models, 40, 41 although derivation from memory and naive subsets was not studied. Thus, we examined potential synergy between adoptively transferred CD4 + CAR-T cells and CD8 + CAR-T cells derived from T CM , which was the most efficacious CD8 subset alone. We first evaluated whether CD4 + CD19 CAR-T cells As CD4 + T cells from patients with B-cell malignancies may be functionally compromised, 42, 43 we analyzed whether helper function was preserved in CD4 + CAR-T cells generated from CD4 + T N , T CM and T EM subsets of CLL patients. The cytokine profile of patient CD4 + CAR-T cells was similar to that observed in normal donors (T N 4T CM /T EM ) suggesting that transduction and culture of T cells from these patients may overcome any functional defects, or result in the selective expansion of T cells that were competent to produce cytokines ( Figure 5b ). As observed with normal donors, the proliferation of CD8 + T CM -derived CAR-T cells from patients after stimulation with a tumor cell line and with the patient's (Figures 5d and e) . Analysis of the frequency of CAR-T cells in the peripheral blood of mice showed that the improved antitumor effect in mice receiving CAR-T cells derived from CD8 + T CM combined with CD4 + T CM or T N correlated with greater peak proliferation of CD8 + T cells in vivo than observed with the CD8 + T CM product alone or with CD4 + T EM , consistent with the hierarchy observed in the in vitro experiments (Figures 5f and g ). We also observed significant in vivo expansion of CD4 + CAR-T cells when administered alone, however, at this cell dose CD4 + CAR-T cells were insufficient to prevent outgrowth of Raji tumors, despite sustained proliferation and persistence for 44 weeks (Figure 5f ).
In healthy donors, T N and T CM are the numerically dominant CD4 + T-cell subsets (Figure 1 ), and we found that CAR-T cells derived from unselected bulk CD4 + were equivalently effective in providing help as sort-purified CD4 + T N and CD4 + T CM , although the enhancement of CD8 + CAR-T-cell proliferation with unselected CD4 + T cells was less than that observed with CD4 + T N -or CD4 + T CM -derived products (data not shown). Our data on the subset distribution in patients with B-cell malignancies eligible for CD19 CAR-T-cell therapy show a marked increase in the proportion of CD4 + T EM , suggesting that improvements in potency in some patients may be achieved by selecting CD4 + T N and T CM subsets before preparing therapeutic products.
Patient CAR-T-cell products of defined subset composition have enhanced potency in vivo To evaluate the potential advantages of preparing cell products of defined subset composition in a clinical setting, we prepared CD19 CAR-T cells from two patients with non-Hodgkin's lymphoma enrolled on an ongoing clinical trial of CAR-T-cell therapy (NCT01865617), and used these cell products to treat NSG mice engrafted with Raji/ffluc. We derived CD19 CAR-T cells from unselected PBMC, or defined populations of sort-purified CD62L (Figure 6b ). NSG mice with Raji tumors were then treated with a fixed total dose of 1 × 10 6 CAR-T cells derived from either PBMC, CD8 + T CM , CD4 + T N , or a combined product of CD8 + T CM and CD4 + T cells (T N or T US ) at a 1:1 ratio. Analysis of tumor progression and survival showed enhanced antitumor efficacy of cell products comprises CD8 + T CM and either CD4 + T N or T US compared with products from PBMC, or from CD8 + or CD4 + T cells alone (Figures 6c and d) . The combination of CD8 + T CM and CD4 + T N conferred the strongest antitumor effect, and long-term tumor-free survival was achieved in all mice in this treatment group (n = 5/5). Complete tumor eradication was also observed in a subset of the mice that received the combination of CD8 + T CM and CD4 + T US (n = 1/5). All mice in the group that received PBMC-derived CAR-T cells expired from progressive tumors. We again found a strong correlation between enhanced antitumor efficacy and superior proliferation of CD8 + CAR-T cells (Figure 6e ). The data show that formulating CD8 + and CD4 + CAR-T cells from defined progeny can provide cell products with increased potency compared with CAR-T cells from whole unselected PBMC or the CD8 + T-cell subset alone.
DISCUSSION
Clinical trials in which peripheral blood T cells were transduced with CD19 CARs containing CD28/CD3ζ or 4-1BB/CD3ζ signaling domains demonstrate a high complete remission rate in acute lymphoblastic leukemia and a significant response rate in CLL and non-Hodgkin's lymphoma. [3] [4] [5] [6] [7] [8] [9] [10] 35, 44 Not all patients respond and toxicities, including cytokine release syndrome, disseminated intravascular coagulopathy and neurotoxicity can occur after infusing CAR-T cells. 3, 6 The follow-up in most trials is short, and the durability of responses remains to be determined. Comparing efficacy and toxicity outcomes in different studies is difficult because of patient heterogeneity and differences in vector design, culture methods and cell doses. [3] [4] [5] [6] [7] [8] [9] [10] 35, 44 Furthermore, our data show that the frequencies of CD4 + and CD8 + T cells, and the proportions of naive and memory cells in each subset, are skewed in patients with B-cell malignancies that have received cytotoxic chemotherapy. Thus, in the absence of selection of defined populations, the phenotype and function of genetically modified cell products prepared from patients will be diverse and reflective of the proportions of CD4 + and CD8 + T cells and memory and naive subsets in the blood. Indeed, clinical trials of CD19 CAR-T cells have administered products that diverge markedly in the proportions of CD4 + and CD8 + T cells, and it is impossible to retrospectively determine the fraction of transduced T cells that were derived from naive or memory T-cell precursors. 3, 35 The efficacy of T-cell therapy is predicated on the ability of transferred cells to proliferate in vivo to overcome numerically larger tumor burdens, migrate to tumor sites, persist and mediate effector functions that destroy tumor cells. Independent of subset derivation, in vitro activated T cells acquire cytotoxicity and cytokine production. However, prior studies in mice and non-human primates have shown that the persistence and function of adoptively transferred effector CD8 + T cells differs depending on the T-cell subsets from which they were derived. The transfer of cytomegalovirus-specific CD8 + T-cell clones derived from T CM but not T EM provided persistent immunity for 44 years; 38, 45 and T-cell receptor transgenic T cells derived from the T N and T CM subsets conferred superior antitumor responses to melanoma than those derived from T EM . 37, 46 Pharmacologic activation of Wnt signaling during the culture of CD8 + T N arrests differentiation at a phenotype intermediate between T N and T CM , and these arbitrarily termed 'memory stem cells' have potent antitumor activity in animals. 47 Human T cells with this phenotype are present in blood as a minor population and when engineered with CARs and administered with CD4 + T cells are effective in tumor xenograft models. 19 However, strategies for purification of this subset for clinical use are not available.
Unlike oncology drugs where dose-response relationships are readily measurable, CAR-T cells prepared from unselected cell populations may vary widely in potency. To provide insight into how variation in common subsets may affect therapy with CAR-T cells, we transduced individual CD8 + and CD4 + T-cell subsets from normal donors and patients with B-cell malignancies with a CD19 CAR. All CD4 + and CD8 + T-cell subsets mediated cytolysis, secreted cytokines and proliferated in response to tumor cells in vitro. Unselected CD4 + CAR-T cells and those derived from T N , T CM and T EM subsets were less cytolytic and produced higher levels of cytokines than unselected CD8 + CAR-T cells. CAR-T cells derived from CD4 + T N produced more cytokines than those derived from CD4 + T CM and T EM , and a similar hierarchy of cytokine production was evident in CAR-T cells derived from CD8 + T cells. These differences in functional properties were evident with T cells from normal donors and from patients with B-cell malignancies, demonstrating that although phenotypic composition was skewed in patients, subset intrinsic functional properties were retained when the T cells were signaled through the CAR.
Differences in antitumor efficacy depending on the phenotype and subset derivation of CAR-T cells were demonstrated by experiments in NSG mice engrafted with CD19 + Raji tumors. The efficacy of CD4 + CAR-T cells derived from different subsets has not previously been examined. Our data show that CD4 + CAR-T cells derived from T N and T CM were more effective than those from T EM , which is the subset that is most increased in frequency in patients. CD8
+ CAR-T cells derived from T CM and T N were also more effective than those derived from CD8 + T EM . There was a correlation between antitumor activity and peak proliferation of CD4 + and CD8 + CAR-T cells, consistent with observations in patients.
A notable finding in our studies of human CD19 CAR-T-cell products that extends prior work in mice with bulk CD4/CD8 T-cell subsets 40, 41 was that the potency was markedly enhanced by formulating CD8 + CAR-T cells derived from T CM with CD4 + CAR-T cells, and especially with CD4 + CAR-T cells derived from T N . Formulating cell products in a 1:1 CD4/CD8 ratio resulted in complete eradication of Raji lymphoma at cell doses that were ineffective with either subset alone. Efficacy correlated with markedly greater proliferation of CD8 + CAR-T cells, suggesting that IL-2 produced by CD4 + T cells (T N 4T CM 4T EM ) was important in sustaining the CD8 + T-cell response. The relevance of these findings to clinical applications was demonstrated by the CAR-T cells represent a new and promising approach to cancer therapy, however, heterogeneity of cell products used in different clinical trials makes it difficult to interpret the basis for therapeutic success or failure. Adoptive therapy with defined cell products will require good manufacturing practice compliant cell selection methods that do not leave bound reagents on the T cells. Advances in cell selection methodologies have recently been made, 36 and it is likely that automated devices will be developed to improve producing T-cell products of defined composition. Identifying the most effective compositions of CAR-T cells will require evaluation in carefully designed clinical trials and may be most critical in solid tumors where target molecules are expressed at lower densities than CD19, and immunosuppressive tumor microenvironments pose an obstacle to tumor eradication. Our results suggest that defining the composition of T cells used in adoptive therapy can enhance antitumor activity, lower the T-cell doses needed for therapeutic efficacy and reduce a major variable that currently complicates comparison of results in individual patients and across studies.
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